Zealand Pharma and Boehringer Ingelheim present promising obesity drug data
Danish Zealand Pharma and its German partner, Boehringer Ingelheim, have served more data from a phase II trial of obesity candidate BI 456906 (survodutide).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Berenberg predicts an obesity market of USD 85bn by 2030
For subscribers